Investment Thesis
HeartBeam is a pre-revenue or early-stage medical device company with severe financial distress, burning approximately $14-21M annually with minimal cash generation. The company's negative profitability metrics (-807% ROE, -360% ROA), combined with unsustainable cash burn rate relative to $4.4M cash reserves, presents existential viability concerns without immediate revenue inflection or capital raise.
Strengths
- Maintains adequate short-term liquidity with 1.90x current ratio and $4.4M cash position
- Zero long-term debt eliminates near-term refinancing risk and provides capital structure flexibility
- Medical device sector (surgical instruments) operates in growing market with recurring revenue potential if commercialization succeeds
Risks
- No revenue generation with approximately 6-months cash runway at current burn rate; imminent capital raise or insolvency risk
- Severe and deteriorating unit economics with -$21M net loss and -$14M operating cash flow indicating fundamental business model failure
- Minimal balance sheet ($5.8M assets) provides no cushion for development delays or clinical setbacks; high dilution risk for existing shareholders from necessary equity financing
Key Metrics to Watch
- Revenue initiation and gross margin sustainability upon commercialization
- Cash burn rate trend and runway to profitability timeline
- Shareholder dilution from capital raises and cumulative losses impact on equity base
Financial Metrics
Revenue
N/A
Net Income
-21.0M
EPS (Diluted)
$-0.62
Free Cash Flow
-14.6M
Total Assets
5.8M
Cash
4.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-807.3%
ROA
-359.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.90x
Quick Ratio
1.86x
Debt/Equity
0.00x
Debt/Assets
55.5%
Interest Coverage
-9.76x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T21:26:10.829834 |
Data as of: 2025-12-31 |
Powered by Claude AI